BiomX Stock Set to Reverse Split on Wednesday, September 9th (NYSEAMERICAN:PHGE)

Shares of BiomX Inc. (NYSEAMERICAN:PHGE) are going to reverse split on the morning of Wednesday, September 9th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 8th.

BiomX Stock Down 0.9%

PHGE stock opened at $0.14 on Tuesday. The firm has a 50-day moving average price of $0.22 and a 200-day moving average price of $1.91. BiomX has a 12 month low of $0.12 and a 12 month high of $12.29. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.66 million, a P/E ratio of -0.04 and a beta of 1.35.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.37) earnings per share for the quarter. The firm had revenue of $0.33 million for the quarter. As a group, equities research analysts anticipate that BiomX will post -5.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.